The Effect of Initial Duloxetine Dosing Strategy on Nausea in Korean Patients with Major Depressive Disorder
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective To assess the relative severity of nausea in patients from Korea with major depressive disorder (MDD) who were treated with duloxetine at low (30 mg) or high (60 mg) doses, with or without food, for the first week of an 8 week treatment. Methods Adult patients (n=249), with MDD and a 17-item Hamilton Rating Scale for Depression (HAMD17) score of ≥15, received openlabel once daily duloxetine. At Week 0, patients were randomized to 4 groups: 30 mg with food (n=63), 60 mg with food (n=59), 30 mg without food (n=64), and 60 mg without food (n=63). At Week 1, all patients switched to duloxetine 60 mg for 7 weeks. The primary outcome measure was item 112 (nausea) of the Association for Methodology and Documentation in Psychiatry adverse event scale. Effectiveness was assessed by change in HAMD17 total score. Results Overall, 94.4% (235/249) of patients completed Week 1 and 55.0% (137/249) of patients completed the study. For Week 1, nausea was significantly less severe for patients who received 30 mg compared with 60 mg duloxetine (p=0.003), regardless of food intake. In all groups, nausea severity was highest at Week 1 and declined throughout the study. HAMD17 score was reduced in all groups and the most common adverse event reported was nausea (145/249; 58.2%). Conclusion To minimize nausea, Korean patients with MDD who require duloxetine treatment could be given 30 mg once daily, regardless of food, for the first week followed by 60 mg once daily for the course of therapy.
Abstract
Objective To assess the relative severity of nausea in patients from Korea with major depressive disorder (MDD) who were treated with duloxetine at low (30 mg) or high (60 mg) doses, with or without food, for the first week of an 8 week treatment. Methods Adult patients (n=249), with MDD and a 17-item Hamilton Rating Scale for Depression (HAMD17) score of ≥15, received openlabel once daily duloxetine. At Week 0, patients were randomized to 4 groups: 30 mg with food (n=63), 60 mg with food (n=59), 30 mg without food (n=64), and 60 mg without food (n=63). At Week 1, all patients switched to duloxetine 60 mg for 7 weeks. The primary outcome measure was item 112 (nausea) of the Association for Methodology and Documentation in Psychiatry adverse event scale. Effectiveness was assessed by change in HAMD17 total score. Results Overall, 94.4% (235/249) of patients completed Week 1 and 55.0% (137/249) of patients completed the study. For Week 1, nausea was significantly less severe for patients who received 30 mg compared with 60 mg duloxetine (p=0.003), regardless of food intake. In all groups, nausea severity was highest at Week 1 and declined throughout the study. HAMD17 score was reduced in all groups and the most common adverse event reported was nausea (145/249; 58.2%). Conclusion To minimize nausea, Korean patients with MDD who require duloxetine treatment could be given 30 mg once daily, regardless of food, for the first week followed by 60 mg once daily for the course of therapy.
참고문헌 (15)
- Qaseem A., "Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians", Ann Intern Med, 149, pp.725~733 (2008)
- Gartlehner G., "The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis", Drug Saf, 32, pp.1159~1173 (2009)
- Lee P., "Once-daily duloxetine60 mg in the treatment of major depressive disorder: multicenter,double-blind, randomized, paroxetine-controlled, non-inferiority trialin China, Korea, Taiwan and Brazil", Psychiatry Clin Neurosci, 61, pp.295~307 (2007)
- Nelson JC., "The safety and tolerability of duloxetine compared With paroxetine and placebo: a pooled analysis of 4 clinical trials", Prim Care Companion J Clin Psychiatry, 8, pp.212~219 (2006)
- Brunton S., "Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies", Drug Saf, 33, pp.393~407 (2010)
- Detke MJ., "Duloxetine60 mg once daily dosing versus placebo in the acute treatment ofmajor depression", J Psychiatr Res, 36, pp.383~390 (2002)
- Greist J., "Incidence and duration of anti-depressant-induced nausea: duloxetine compared with paroxetine and fluoxetine", Clin Ther, 26, pp.1446~1455 (2004)
- Dunner DL., "Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg starting doses", Curr Ther Res, 66, pp.522~540 (2005)
- Mallinckrodt CH., "Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range", J Psychiatr Res, 40, pp.337~348 (2006)
- Whitmyer VG., "A comparison of initial duloxetine dosing strategies in patients with major depressive disorder", J Clin Psychiatry, 68, pp.1921~1930 (2007)
- Hamilton M., "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
- Stieglitz RD., "The AMDP System, In The International Classification in Psychiatry", pp.180~204 (1988), Cambridge University Press
- Guy W., "ECDEU Assessment Manual for Psychopharmacology. Washington", pp.218~222 (1976), US Department of Health, Education and Welfare
- Chen PY., "Biological variations in depression and anxiety between East and West", CNS Neurosci Ther, 15, pp.283~294 (2009)
- Epstein WV., "Expectation bias in rheumatoid arthritis. The anti-CD4 monoclonal antibody experience", Arthritis Rheum, 39, pp.1773~1780 (1996)